Regenerative Medicine Firm Prepares for Inaugural Wellness Facility in Southeast Asia
Celularity announced progress toward the first-quarter 2027 opening of Fontaine Vitale, a regenerative medicine and wellness center in Bali, Indonesia, developed in partnership with Genting Berhad. The facility will be the first in the ASEAN region to offer placenta-derived stem cell therapies, leveraging Celularity's manufacturing capabilities and creating new market opportunities across Asia-Pacific. The approximately 172,000-square-foot facility will serve both local and international patients seeking longevity and regenerative medicine treatments.
Celularity specializes in developing cellular therapies derived from postpartum placental tissue, targeting age-related conditions and longevity applications. The company operates a certified manufacturing facility in New Jersey that will supply products to the new Indonesian center, positioning the firm to serve a previously untapped market across Southeast Asia and the broader region.
Fontaine Vitale will occupy a substantial four-story complex in Indonesia's first medical-tourism special economic zone, designed to attract both regional patients and international visitors. Initial treatment offerings will emphasize wellness optimization, anti-aging protocols, joint and mobility concerns, and skin restoration through physician-supervised protocols.
The facility could expand access to regenerative medicine approaches in a region with growing healthcare demand and medical-tourism interest. Success may validate business models combining advanced cellular therapies with destination wellness facilities, potentially influencing how similar treatments are positioned globally. Questions remain regarding long-term efficacy data, regulatory pathways, and equitable access to expensive regenerative treatments across different patient populations.